Ngna compositions and methods of use

a composition and ngna technology, applied in the field of ngna compositions and methods of use, can solve the problems of increasing the chance of viruses spreading from person to person, difficult to assess the importance of coronaviruses as causative agents, and people spending more time indoors, so as to prevent the onset of colds, improve energy, and reduce the symptoms of colds

Inactive Publication Date: 2010-05-13
LIFE SCI NUTRITION AS
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]The present invention relates to the use of compositions comprising n-glycolylneuraminic acid (NGNA). Compositions comprising NGNA find use in inducing physiological responses such as

Problems solved by technology

The importance of coronaviruses as causative agents is hard to assess because, unlike rhinoviruses, they are difficult to grow in the laboratory.
The seasonal variation may relate to the opening of schools and to cold weather, which prompt people to spend more time indoors and increase the chances that viruses will spread from person to person.
Colds occasionally can lead to secondary bacterial infections of the middle ear or sinuses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ngna compositions and methods of use
  • Ngna compositions and methods of use
  • Ngna compositions and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0102]A sports drink containing NGNA was formulated for use by humans. The NGNA was made from glucosamine residues derived from crab chitin. The finished drink (per 500 ml bottle) contained: pure water; 1% Glycerol / (0, 1-10%); lemon flavor; potassium sorbate / sodium benzoate as stabilizers; and 2 mg of 99% pure NGNA.

example 2

[0103]The sports drink described in Example 1 was tested in a group of 18 subjects. The subjects were supplied one 500 ml bottle of the sport drink containing 2 mg NGNA. The drink was administered during exercise or during the day when not exercising over an eight week period. The subjects worked out an average of about four times per week. The following measurements were taken during the study: fett / fat %, vekt / weight, overarm / upper arm in cm, midje / waist in cm, l∪r / thighs in cm. These results are summarized in FIG. 1A. As can be seen, there was a steady decrease in weight during the study (FIG. 1B). The subjects were also asked to evaluate other physiological effects of the drink. The subjects were asked to rank the impact of the drink on a scale of 0 to 9 (with 9 being a positive impact) with respect to the following questions:

[0104]a. How was your workout today

[0105]b. How do you feel?

[0106]c. Do you have a cold 0, or are you healthy 9?

[0107]d. Do you feel the drink helps you?

[0...

example 3

[0110]This example describes the in vitro inhibition of various viruses by compositions comprising NGNA.

Influenza

[0111]The Influenza B virus that will be used for this study will be B / Malaysia.[0112]Source: Retroscreen Virology Ltd. Virus B / Malaysia / 2506 / 2004[0113]Physical form: Virus in liquid medium[0114]Expiry date: 4 hours after dilution[0115]Storage conditions: On ice[0116]Safety precautions: Biosafety Level 2 containment conditions

[0117]The cell line to be used in Phase A is MDCK cells. The Growth Media for the MDCK cell line is DMEM, 2 mM L-Glutamine, 10% FBS (foetal bovine serum) and 2 mM Hepes buffer. The Infection Media for the MDCK cell line is DMEM, 2 mM L-Glutamine, 2 mM Hepes buffer and 1.5 mM Trypsin (TPCK treated).

[0118]In the virucidal assay the Influenza B virus titrations will be incubated for 2 to 3 days before the efficacy of the test article on the virus will be determined by HA (Haemagglutination Assay). This assay utilizes the ability of influenza virus to bi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application Ser. No. 61 / 113,048, filed: Nov. 10, 2008, which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to the use of compositions comprising n-glycolylneuraminic acid (NGNA). Compositions comprising NGNA find use in inducing physiological responses such as alleviating the symptoms of colds and preventing the onset of colds.BACKGROUND OF THE INVENTION[0003]In the course of a year, individuals in the United States suffer 1 billion colds, according to some estimates. Colds are most prevalent among children, and seem to be related to youngsters' relative lack of resistance to infection and to contacts with other children in day-care centers and schools. Children have about six to ten colds a year. In families with children in school, the number of colds per child can be as high as 12 a year. Adults average about two ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/12A61K31/7004C12N7/06A61K9/00A01N25/02A01N43/04A61P31/14A61P31/20A01P1/00
CPCA61K31/7012A61K31/351A61P31/14A61P31/16A61P31/20A61K9/0043A61M31/00A61M2210/0618
Inventor REMMEREIT, JANEDWALL, DANSTRUKSNES, ANDERS
Owner LIFE SCI NUTRITION AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap